ENPICOM receives subsidy for R&D partnership project

DTL Partner ENPICOM and Glycostem receive MIT Zuid subsidy to support their R&D partnership project of over half a million euro to develop technology to predict the outcome of an NK-cell-based immunotherapy treatment.

On December 6, DTL partner ENPICOM B.V. and Glycostem Therapeutics BV, announced that their joint MIT Zuid R&D partnership subsidy has been granted. The aim of the collaboration is to develop technology to predict the outcome of an NK-cell-based immunotherapy treatment in patients with incurable locally advanced or metastatic solid tumors, for which there is no standard therapy.

Read more

 

This entry was posted in Partner.

Comments are closed.